Klingenstein Fields & Co’s VanEck Pharmaceutical ETF PPH Stock Holding History

Klingenstein Fields & Co’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,800	Closed	-$216K	–	218
2018 Q1	$216K	Hold	3,800	–	–	0.01%	206
2017 Q4	$225K	Hold	3,800	–	–	0.01%	207
2017 Q3	$219K	Hold	3,800	–	–	0.01%	204
2017 Q2	$224K	Hold	3,800	–	–	0.01%	206
2017 Q1	$210K	Buy	+3,800	New	+$206K	0.01%	214
2016 Q4	–	Sell	-5,000	Closed	-$287K	–	234
2016 Q3	$287K	Hold	5,000	–	–	0.01%	185
2016 Q2	$293K	Hold	5,000	–	–	0.01%	178
2016 Q1	$287K	Buy	5,000 +1,200	+32%	+$71K	0.01%	177
2015 Q4	$248K	Hold	3,800	–	–	0.01%	194
2015 Q3	$239K	Hold	3,800	–	–	0.01%	200
2015 Q2	$269K	Sell	3,800 -1,000	-21%	-$72K	0.01%	210
2015 Q1	$337K	Hold	4,800	–	–	0.01%	190
2014 Q4	$308K	Hold	4,800	–	–	0.01%	198
2014 Q3	$305K	Hold	4,800	–	–	0.01%	200
2014 Q2	$298K	Hold	4,800	–	–	0.01%	205
2014 Q1	$280K	Hold	4,800	–	–	0.01%	216
2013 Q4	$255K	Hold	4,800	–	–	0.01%	271
2013 Q3	$230K	Hold	4,800	–	–	0.01%	280
2013 Q2	$218K	Buy	+4,800	New	+$222K	0.01%	295

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Klingenstein Fields & Co's PPH Position: Q2 2018 in Review

Klingenstein Fields & Co sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2018, closing a stake of 3,800 shares — an estimated $216K sold.

Klingenstein Fields & Co first reported a position in PPH in Q2 2013 and held it in 19 quarters. The position peaked at $337K in Q1 2015. 49 funds tracked by Wall St. Rank hold PPH as of Q2 2018.

Klingenstein Fields & Co reported no remaining VanEck Pharmaceutical ETF position as of Q2 2018 after selling out during the quarter.
Klingenstein Fields & Co sold 3,800 VanEck Pharmaceutical ETF shares in Q2 2018, an estimated $216K.
Klingenstein Fields & Co first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and held it in 19 quarters.
Klingenstein Fields & Co's VanEck Pharmaceutical ETF position peaked at $337K in Q1 2015.
49 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2018.

Based on Klingenstein Fields & Co's 13F filing for Q2 2018, filed 26 Jul 2018.